Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 20;15:1437267. doi: 10.3389/fimmu.2024.1437267

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Bai, Zhou, Zhang, Chen, Lv, Wang, Zhang, Wu and Zhao

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Non-inferiority for SARS-CoV-2 neutralizing antibody geometric mean titer (GMT) ratios and seroconversion rate of co-administration versus separate administration. Blood samples were collected 28 days after each group received CoronaVac. Neutralizing antibodies against live Wuhan-Hu-1 strain were quantified using the micro cytopathogenic effect assay. The GMT ratios (A) and differences in seroconversion rates (B) were compared between the co-administration groups and the SARS-CoV-2/PPV23+IIV4 group. The dashed lines represent the 95% CI lower boundary of 0.5 for GMT ratios and -10% for the seroconversion rate differences.